Therefore, targeting JMJD2D could attenuate CSC self-renewal through simultaneously inhibiting Wnt, Notch, and Hedgehog signaling pathways, which have great potential for the clinical treatment of liver cancer patients. The gene discussed is KDM4D; the disease is liver cancer.